We systematically searched MEDLINE (PubMed), Embase, and ClinicalTrials.gov for interventional phase I-III clinical trials evaluating PARP inhibitors combined with PD-1/PD-L1 inhibitors in ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancer between January 1, 2015, and August 24, 2025. This evidence concerns the gene PDCD1 and cervical carcinoma.